First United Bank & Trust cut its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 30.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,896 shares of the company's stock after selling 4,380 shares during the period. First United Bank & Trust's holdings in Johnson & Johnson were worth $1,641,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Tallon Kerry Patrick bought a new position in Johnson & Johnson in the fourth quarter valued at about $290,000. Capital & Planning LLC lifted its holdings in Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after buying an additional 183 shares during the period. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Union Bancaire Privee UBP SA acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $85,886,000. Finally, Apollon Wealth Management LLC lifted its holdings in Johnson & Johnson by 20.7% in the fourth quarter. Apollon Wealth Management LLC now owns 105,500 shares of the company's stock valued at $15,257,000 after buying an additional 18,082 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on JNJ shares. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Wednesday, April 16th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Barclays cut their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.
View Our Latest Analysis on JNJ
Johnson & Johnson Stock Up 0.2%
Shares of JNJ stock traded up $0.24 during trading hours on Friday, hitting $156.90. 6,587,488 shares of the company were exchanged, compared to its average volume of 7,963,253. The company has a market capitalization of $377.52 billion, a PE ratio of 23.59, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The business has a 50 day moving average of $153.84 and a two-hundred day moving average of $153.71. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
